Cellectar Biosciences, Inc. (CLRB) analyst actions
Rating and price-target actions on CLRB in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the CLRB overview →
1 measured CLRB analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer | Press release | -3.18% | -3.64% |
Keep exploring
More CLRB: earnings → · SEC filings → · CLRB overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Qiagen N.V. Common Shares (QGEN) | 266 | +0.05% | 53% |
| 22nd Century Group, Inc (XXII) | 266 | -1.87% | 30% |
| EVOTEC AG S/ADR (EVTCY) | 265 | 0.00% | 17% |
| MiMedx Group, Inc (MDXG) | 265 | +0.14% | 57% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.